Last updated: 2026-09-10 01:47:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
ADC Therapeutics SA (ADCT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $1.22, with a market capitalization of $173.63M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.78 to $4.98. This page covers its latest market performance, valuation, price trends and company information.
$173.63M | |
$1.28 | |
$56.59 | |
$0.36 | |
$1.30 | |
1.64M | |
1.60M | |
-- | |
$4.98 | |
$0.78 | |
-- | |
-- |
ADC Therapeutics SA (ADCT) last closed at $1.30 as of 2026-09-09 23:31:00, unchanged from the previous close of $1.30.
During the latest regular trading session, ADCT traded between $0.36 and $56.59, with a volume of 1.64M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, ADC Therapeutics SA (ADCT) moved from $1.14 to $1.22, representing a gain of 6.67% ($0.08).
The stock traded between $1.07 and $1.37 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 1.73 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 10.4%
ADCT is currently trading at $1.22, placing it 10.4% of the way from its 52-week low of $0.78 to its 52-week high of $4.98. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 193 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of ADC Therapeutics SA (ADCT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.